** Shares of biotech firm Aligos Therapeutics ALGS.O rise 3.8% to $27 premarket
** ALGS says it is raising $105 million in a private placement financing
** Co is selling ~2.1 million shares of common stock along with warrants to purchase up to ~2 million additional shares at a combined purchase price of $26.0825/shr
** Combined purchase price is at a 0.2% premium to the stock's last close
** Co says the funding will be used to start a mid-stage trial for ALG-000184, a treatment for chronic hepatitis B virus infection
** Co says the funding will extend its cash runway into the H2 of 2026
** Co has 3.6 million outstanding shares, with market cap of $93.4 million - LSEG data
** Jefferies and Piper Sandler are acting as placement agents
** ALGS shares more than doubled in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。